Long-term outcome of postoperative interferon-α adjuvant therapy for non-metastatic renal cell carcinoma

International Journal of Urology

Volumn 11, Issue 5, 2004, Pages 257-263

  Gotoh, Akinobu ^a   Shirakawa, Toshiro ^a   Hinata, Nobuyuki ^a   Wada, Yoshitaka ^a   Hara, Isao ^a   Fujisawa, Masato ^a   Kawabata, Gaku ^a   Okada, Hiroshi ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant therapy; Interferon ; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; IMMUNOSUPPRESSIVE ACID PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NONRECURRENCE RISK; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2942527226     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00798.x     Document Type: Article

References (15)

1. Satomi Y. Current status of treatment of renal cell carcinoma and future problems. Jpn. J. Urol. 1990; 81: 1-13.
2. Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 2001; 19: 425-31.
3. Vuky J, Motzer RJ. Cytokine therapy in renal cell cancer. Urologic Oncol. 2000; 5: 249-57.
4. Soret JY, Escudier B. Adjuvant treatment with IL-2 or interferon-alpha in renal cell carcinoma: a French multicentric study. Cancer Biother. Radiopharm. 1996; 11: 301-2.
5. Jeon SH, Chang SG, Kim JI. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res. 1999; 19: 5593-7.
6. Basting R, Corvin S, Handel D et al. Adjuvant immunotherapy in renal cell carcinoma comparison of interferon alpha treatment with an untreated control. Anticancer Res. 1999; 19: 1545-8.
7. Aso Y, Homma Y, Arai Y et al. The efficacy of α-interferon in renal cell carcinoma with special reference to adjuvant therapy. Urologic Surg. 1995; 8: 333-44.
8. Migliari R, Muscas G, Solinas A et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J. Chemotherapy 1995; 17: 240-45.
9. Japanese Urological Association, The Japanese Society of Pathology (eds). General rule for clinical and pathological studies on prostatic cancer, 2nd edn. WB Saunders Co., Philadelphia, 1998.
10. Soblin LH, Wittekind C. TNM Classification of Malignant Tumors, 5th edn. John Wiley, New York, 1997.
11. Pummer K, Purstner P, Auner HL et al. Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma. Br. J. Urol. 1994; 73: 612-4.
12. Sasagawa I, Nakada T, Kubota Y et al. Serum level of immunosuppressive acidic protein in haemodialysis patients with or without renal cell carcinoma. Br. J. Urol. 1994; 73: 355-7.
13. Masuda H, Kurita Y, Suzuki K et al. Predictive value of serum immunosuppressive acidic protein for staging renal cell carcinoma: comparison with other tumour markers. Br. J. Urol. 1997; 80: 25-9.
14. Igarashi T, Tobe T, Kuramochi H et al. Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 2001; 31: 13-7.
15. Mickisch GH, Garin A, van Poppel H et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Lancet 2001; 358: 966-70.